Skip to content

Author

Robert A. Rissman

We have 5 of 33 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Association between early‐life farming exposure and Alzheimer's disease neuropathological burden

Abstract BACKGROUND Farming populations may face a disproportionate share of adverse exposures influencing Alzheimer's disease (AD), yet farming data are rarely connected to cohorts with characterized AD neuropathology. Whether early‐life exposure is related to AD neuropathology is limited. METHOD Brain donors from two...

W. Powell, Eleanna M. Melcher, Rachel C. Otte et al. · 0 citations
Open access Oct 2026

ATRI LIMS: a cloud-native open-source laboratory information management system for biomarker-driven Alzheimer’s disease clinical trials

Abstract Objectives This article summarizes the architecture, design principles, and implementation strategy of the ATRI Laboratory Information Management System (LIMS), a cloud‑native, open‑source platform supporting biomarker‑driven Alzheimer’s disease (AD) clinical research. The system addresses challenges associate...

G. Jimenez-Maggiora, S. Bruschi, S. Abdel-Latif et al. · 0 citations
Open access Sep 2026

Cardiovascular risk factors and regional neuropathology in autopsy-confirmed Alzheimer disease.

Cardiovascular risk factors are implicated in Alzheimer disease (AD) progression and its neuropathological hallmarks but their specific contributions to regional brain pathology within AD remain understudied. In this cohort study (n = 276), we examined associations between diabetes, hypertension, and hypercholesterolem...

David Garcia, Hsin-Pei Wang, Naomi Saito et al. · 0 citations
Open access Sep 2026

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with few treatment options, especially for APOE4/4 homozygotes who carry high genetic risk. Valiltramiprosate/ALZ-801 is an oral small-molecule inhibitor of amyloid-beta oligomer formation in late-stage development as a disease-modifying therapy for A...

J. Hey, S. Abushakra, A. Power et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.